Introduction
Tumor cells can express unique antigens which are presented tion require additional co-stimulatory signals (10) that are provided by the interaction of several T cell surface receptors by MHC molecules and recognized by T lymphocytes (1) (2) (3) (4) (5) (6) (7) (8) (9) . The presence of such antigens, therefore, identifies tumor with their respective ligands on professional antigen-presenting cells (APC) (11) . Antigen recognition in the absence cells as targets for specific T lymphocytes. In most cases tumor cells fail to initiate immune responses. One major of co-stimulatory signals results in unresponsiveness and induces specific anergy (10) . Ligation of CD28, which is reason for this poor immunogenicity is the lack of cell surface molecules which are required for optimal T lymphocyte expressed on both resting and activated T cells, produces crucial co-stimulatory signals for T cell activation resulting in activation.
Ligation of the TCR with antigen-MHC represents the augmented cytokine release by increasing cytokine mRNA stability and promoting cell proliferation (12, 13) . Furthermore, primary signal for T cell activation and determines the specificity of the immune response. IL-2 secretion and cell prolifera-CD28 triggering can prevent the induction of anergy (14) .
CD28 binds to CD80 (B7-1) and CD86 (B7-2), which are (Wellcome, Burgwedel, Germany) for 5 days at a final concentration of 0.5 µg/ml. co-expressed on dendritic cells, activated macrophages and B lymphocytes (15) (16) (17) (18) . Both ligands of CD28 were reported Cloning of human CD86 to co-stimulate T cell activation in a similar fashion (19) ; however, it was also suggested that CD80 and CD86 activate RNA isolated from the human B-LCL-line LAZ509 was reverse transcribed using random priming. The human CD86 cDNA different T helper subpopulations (20,21). CTLA-4, which is expressed following activation of T lymphocytes, is known as fragment was subsequently amplified using oligonucleotides priming in the 5Ј and 3Ј untranslated region of the CD86 a second receptor for both CD80 and CD86 (15) (16) (17) 22) . In contrast to CD28, stimulation of CTLA-4 was found to inhibit sequence, respectively, (5Ј primer: 5Ј-ACG GGG AGC TCG CAA ATA CTC-3Ј; 3Ј primer: 5Ј-CTG CCC CCT TAT TAC TCA T cell activation suggesting a negative regulatory function of CTLA-4 (23-25).
T-3Ј). The 1227 bp PCR fragment was cloned directly in the pCR vector of the TA cloning system (Invitrogen, Leek, The absence of co-stimulatory molecules on the cell surface of tumor cells could, at least in part, explain their low immunoNetherlands) and sequenced using an automated laser fluorescence sequencing system (ALF; Pharmacia). Except for genicity and even provide a concept to explain the induction of tolerance. Therefore, the expression of co-stimulatory moleone nucleotide difference at position 365 (A to G) changing a histidine residue into arginine, the CD86 sequence was cules on tumor cells via somatic gene transfer may represent a potent way to generate variants capable of stimulating T cell identical to the sequence previously published (17) . This relative conservative alteration could be induced early in the responses towards the antigens presented on their surface. Indeed, the expression of CD80 or CD86 on murine tumor PCR reaction or could represent an allelic variant of CD86. It is located at a position not conserved between CD80 and cell variants resulted in tumor cell rejection and the induction of protective immune responses in vivo (26) (27) (28) (29) . We and CD86. The biological function of the CD86 protein derived from this sequence was confirmed by CD86 mAb binding others demonstrated that CD80 expression augmented the immunogenicity of human tumor cells in vitro (30) (31) (32) . Howand T cell co-stimulation. The CD86 fragment was isolated from pCR-CD86 either as a KpnI-XbaI or as a SpeI-NotI ever, these experiments also indicated that in some cases CD80 was not sufficient to induce T cell proliferation and fragment and cloned into the eukaryotic expression vectors pUHD10-1 (Dr H. Bujard, Universitä t Heidelberg, Germany; suggested that additional molecules may be required (30).
Cytokines have been tested in murine models for their KpnI-XbaI digested) to yield pUHD10-1-CD86 or into pRcRSV (Invitrogen; SpeI-NotI digested) to yield pRcRSV-CD86. capacity to support immune responses against syngeneic tumor cells following gene transfer and endogenous expresTransfections sion. Among them, IL-2, IL-4, tumor necrosis factor (TNF)-α and IFN-γ were found to induce specific T lymphocytes
The CD80-transfected SkMel63 variant SkMel63A3 was described earlier (30). For transfection with CD86, parental capable of protecting animals from subsequent challenge with unmodified tumor cells (33) (34) (35) (36) . These effects can be SkMel63 cells were plated, at 2ϫ10 6 /10 cm dish and transfected with XmnI-linearized pUHD10-1-CD86 together with explained in at least two ways: (i) cytokines either augment the capacity of the phagocytic compartment to present tumor EcoRI-linearized pSV2-neo at a ratio of 10:1, using 10 µg DNA and 20 µg Lipofectin (Gibco) according to the manufacturer's antigens or (ii) directly act on the activation of tumor-specific T lymphocytes.
protocol. SkMel63A3 cells were co-transfected using 10 µg pUHD10-1-CD86 and 1 µg pX343 plasmid DNA (Dr H. Bujard) Here, a human melanoma cell line transfected with the costimulatory molecules CD80 and/or CD86 was tested for its providing hygromycin resistance. Selection was performed using either 1 mg/ml G418 (Gibco) alone or G418 together capacity to promote the primary proliferation of resting human allogeneic T lymphocytes in the presence of several cytokines.
with 100 µg/ml hygromycin (Merck, Darmstadt, Germany). Bulk cultures were analyzed by immunofluorescence using a Our study demonstrates that IL-12 exhibits differential activities in conjunction with CD80 as compared to CD86.
CD86-specific mAb (clone IT2.2). Positive fractions were sorted by means of magnetic cell sorting and further expanded.
Methods
Magnetic cell sorting Cells CD86-expressing SkMel63 sublines were incubated with the CD86-specific mAb IT2.2 (2 µg/ml) for 1 h at 4°C in complete The human melanoma cell line SkMel63, kindly provided by Dr A. Knuth (Nordwestkrankenhaus, Frankfurt/Main, Germany), medium. Cells were then washed and incubated with a secondary antibody coupled to magnetic beads (Miltenyi was cultured in DMEM (Gibco, Eggenstein, Germany) supplemented with 10% FCS (Serva, Heidelberg, Germany), 2 mM Chemicals, Bergisch-Gladbach, Germany) at 4°C for 15 min. Cells were then sorted magnetically using mini-MACS columns L-glutamine (Gibco) and 1% penicillin/streptomycin (Gibco). Peripheral blood mononuclear cells were prepared from peri-(Miltenyi Chemicals) according to the manufacturer's protocol. The percentage of CD86 ϩ cells was determined by immunopheral blood of healthy donors by density gradient centrifugation using Ficoll (Ficoll-Hypaque; Pharmacia, Uppsala, fluorescence. The same method was used for the separation of CD4 ϩ Sweden). T lymphocytes were subsequently prepared by adherence on plastic dishes followed by rosetting with sheep and CD8 ϩ subsets from resting T cells using either anti-CD4 ascites (19Thy5D7 provided by Dr E. Reinherz, Boston, MA) erythrocytes. Phytohemagglutinin (PHA) preactivated T cells were obtained by incubating resting T cells with PHA or anti-CD8 ascites (AICD8.1) diluted 1:500. The percentage of selected CD4 ϩ and CD8 ϩ subsets was determined by immunofluorescence. In both cases Ͼ95% pure populations were obtained.
Flow cytometry analysis
Indirect immunofluorescence was performed as described (28). The following mAb were used: clone 104 (anti-CD80, 1 µg/ml; Dianova, Hamburg, Germany) and IT2.2 (anti-CD86, 2 µg/ml; Dianova). FITC-labeled anti-mouse Ig (Dako, Hamburg, Germany) diluted 1/40 in culture medium was used as a secondary antibody. The secondary antibody alone was used as negative control and 5000 cells were analyzed on a Coulter Profile 1 flow cytometer (Coulter Electronics, Hialeah, FL) with logarithmic amplification (3 log scale) through a viable cell tion period of 18 h. Thymidine incorporation was determined by liquid scintillation counting and expressed as mean c.p.m. of triplicate wells. The following cytokines were added to the culture medium: natural human IL-2 (50 U/ml; provided by substrate solution and quantified with an ELISA reader at 405 Biotest, Dreiech, Germany), recombinant IL-4 (50 U/ml; nm (SLT Labinstruments, Crailsheim, Germany). IL-4 was Boehringer Mannheim, Mannheim, Germany), recombinant determined by means of a commercial ELISA according to TNF-α (25 ng/ml; Boehringer Mannheim), recombinant IL-12 the manufacturer's protocol (Genzyme). (0.1, 0.5 and 2 ng/ml; R&D Systems, Wiesbaden, Germany) and recombinant IFN-γ (1, 2, 5, 10, 20 and 50 U/ml; Boehringer Mannheim). In antibody blocking experiments an anti-IFNResults γ mAb (Genzyme, Cambridge, MA) was used at a final CD80 and CD86 SkMel63 melanoma transfectants similarly concentration of 5 µg/ml.
induce
proliferation of resting T cells Propagation of T cells
The human melanoma cell line SkMel63 does not induce significant proliferation of resting allogeneic T lymphocytes in vitro. T lymphocytes (2ϫ10 6 ) were co-cultured in 24-well plates with 2ϫ10 5 γ-irradiated (200 Gy) stimulator cells and reHowever, as previously reported, CD80 expression in SkMel63 cells after gene transfer resulted in the induction stimulated at weekly intervals under identical conditions with the exception that IL-2 was added at 50 U/ml on the third of a strongT cell response (30). In order to determine the effects of CD86 expression and CD80/CD86 co-expression on the day of the second stimulation (day 10).
T cell response, stable SkMel63 transfectants were generated. Determination of IFN-γ and IL-4 Figure 1 (B) shows cell surface expression levels of thetransfected molecules of one representative CD80 ϩ subline Cell culture supernatants of mixed T cell cultures were harvested at various time points and the concentrations of IFN-(SkMel63A3), one representative CD86 ϩ (SkMel63B12) and two double-positive sublines (SkMel63A3B13 and SkMel-γ and IL-4 were determined by specific ELISA. IFN-γ was determined according to the protocol of Gallati (37) . ELISA 63A3B22). Transfected sublines exhibit different cell surface levels of the ligands for CD28/CTLA-4 with sublinesSkMelplates (Nunc) were coated with 100 µl mouse anti-human IFN-γ (5 mg/ml in 100 mmol/l NaHCO 3 , at room temperature, 63A3B13 and SkMel63A3B22 showing highest expression. This becomes particularly obvious following combined labeling over night), washed with deionized water and blocked overnight by incubation with 1% BSA in 200 mmol/l Tris-HCl, pH of CD80 and CD86 (black bars in Fig. 1B) . Expression of CD54, CD58, and MHC class I and class II molecules is comparable 7.5, at room temperature. Subsequently samples were mixed with 100 µl 'ready to use antibody peroxidase test solution' in all cell lines analyzed (not shown). Individual SkMel63 transfectants were then analyzed for (6 µg/ml anti-human IFN-γ-peroxidase in 100 mmol/l sodium phosphate buffer, pH 6.5, 10% FCS) and incubated overnight their ability to promote T lymphocyte proliferation. As shown in Fig. 1(A) , expression of CD80 or CD86 induces pronounced at 4°C. Finally, plates were washed, positive wells were visualized with 2,2Ј-azino-di-(ethylbenzthiazolin-sulfonate)
T cell proliferation, whereas untransfected SkMel63 cells were shown). This shows (i) that there is no correlation between cell surface level expression of ligands for CD28/CTLA-4 and the amount of T cell proliferation, (ii) that CD80 and CD86 are equally effective in T cell activation, and (iii) that coSkMel63 cells to induce MHC class I-restricted (allo-antigen directed) T cells. expression of CD80 and CD86 has no additive or synergistic effect on the T cell response.
IL-12 suppresses the proliferative response towards CD80-Since SkMel63 cells and transfected variants express MHC transfected melanoma cells class I and class II molecules, they could potentially stimulate both CD4 ϩ and CD8 ϩ T lymphocytes. In order to test whether Cytokines can augment T lymphocyte activation by directly acting on T cells or indirectly by up-regulating cell adhesion CD80 and CD86 would perhaps differentially affect the activation of CD4 ϩ and CD8 ϩ T lymphocytes, purified subpopulamolecules. We observed that exogenously added IL-2, IL-4 and TNF-α respectively augmented T cell proliferation towards tions were separately stimulated with CD80 ϩ and CD86 ϩ SkMel63 variants. Figure 2 shows that both CD4 ϩ and CD8 ϩ SkMel63 cells (data not shown). This effect was, however, independent of the expression of CD80 and CD86 respect-T cells were activated by CD80-as well as CD86-transfected SkMel63 cells, and that no major difference between CD80
ively. Because IL-12 was reported to synergize with CD80 in promoting T cell activation (38,39) we also studied the and CD86 was observed.
The activation of CD8 ϩ T cells was also observed when influence of IL-12. Interestingly, the T cell response to CD80-versus CD86-transfected melanoma cells in the presence of unseparated T cells were repetitively stimulated with CD80-and CD86-transfected SkMel63 cells respectively. Independ-IL-12 was not uniform. As shown in Fig. 3(A) , the response to CD86-transfected cells was slightly enhanced whereas ent of the use of CD80 or CD86 transfectants as stimulators, activated T cells displayed cytolytic activity towards untranslymphocyte proliferation in response to CD80-transfected SkMel63 cells was strongly inhibited by exogenous IL-12. In fected SkMel63 cells. This activity was inhibited by MHC class I-but not a MHC class II-specific mAb or by NK cell the case of CD80/CD86-co-transfected SkMel63 cells, T cell proliferation was also reduced by IL-12; however, inhibition inhibition (addition of K562 cells) (not shown). This further confirms the potential of both CD80-and CD86-transfected was only partial, indicating a potential protective effect of wild-type SkMel63. In contrast, IL-4 was not detectable in the induction of cell death to be responsible for the inhibition supernatants by ELISA at two different time points following of T cell proliferation. In order to exclude interclonal variability primary T cell stimulation. However, following re-stimulation between different transfected sublines to be responsible for of T cells with the same melanoma cell variants as before, the opposite effects of CD80 and CD86 transfectants, we we found that both, CD80 ϩ and CD86 ϩ , but not untransfected performed similar experiments with transiently transfected SkMel63 cells induced the release of similar levels of IL-4. SkMel63 cells. Again, IL-12 inhibited T cell proliferation (30% Therefore and in contrast to previous results (20), we did not decrease) in the presence of CD80-but not CD86-transfected observe a difference between CD80 and CD86 in inducing T cells (not shown). Since those reports describing a synergy helper responses. between CD80 and IL-12 used preactivated T lymphocytes, we performed similar experiments with PHA blasts. Generally, IFN-γ suppresses CD80-but not CD86-induced T cell prolifthe response of PHA blasts towards transfected SkMel63 eration cells was low in the absence of IL-12 as shown in Fig. 3(B) . However, and more in line with previous results (39) , an up Since IL-12 induces IFN-γ release following T cell stimulation with CD80 ϩ and CD86 ϩ melanoma cells, the effect of exogento 4-fold increase in lymphocyte proliferation was observed in roughly one-third of the experiments. More importantly, ous IFN-γ on T cell activation in response to SkMel63 variants was analyzed. As shown in Fig. 5 , T cell proliferation induced addition of IL-12 strongly augmented proliferation of PHA preactivated T cells in the presence of either CD80 ϩ , CD86 ϩ by CD80-transfected SkMel63 cells was already inhibited at low concentrations of exogenous IFN-γ. In contrast, IFN-γ did or CD80 ϩ /CD86 ϩ double transfectants. These experiments indicate that, in contrast to preactivated T cells, CD80 and not suppress T cell proliferation induced by CD86-transfected SkMel63 cells (Fig. 5) . It should be mentioned that we did CD86 exert differential effects on the activation of resting T cells in combination with IL-12.
not observe any inhibitory activity of IFN-γ on the proliferation of preactivated PHA blasts in such experiments where CD80-CD80-and CD86-transfected melanoma cells promote the or CD86-transfected SkMel63 cells directly induced their production of IFN-γ spontaneous proliferation (results not shown). Given the above result it seemed possible that the inhibitory effect of IL-12 on Some effects of IL-12 are known to be mediated via the induction of IFN-γ release by T lymphocytes (40,41) directing the activation of resting T cells was mediated by IFN-γ. To further confirm this, we included a neutralizing IFN-γ-specific an immune response towards a T h 1 phenotype. Therefore, we determined the effect of IL-12 on IFN-γ secretion by T mAb in our experiments. As shown in Fig. 6 , the inhibitory activity of IL-12 on T cell proliferation induced by CD80-cells stimulated with transfected SkMel63 variants. Moreover, the release of IL-4 was also determined in order to study a transfected SkMel63 cells (30% inhibition) was completely reversed by an anti-IFN-γ mAb. The slight IL-12-induced possible T h 2 response. Figure 4 shows that incubation of resting T cells with CD80-transfected (SkMel63A3) and CD86-increase in T cell proliferation in the presence of untransfected or CD86 ϩ melanoma cells remained unaffected, however transfected (SkMel63B12) cells respectively resulted in the release of significant amounts of IFN-γ (45 pg/ml and 66 pg/ml (Fig. 6 ). These findings further suggest a participation of IFN-γ in IL-12-mediated inhibition. respectively). When T cells were incubated with untransfected cells also induced CD8 ϩ T lymphocytes in the absence of CD4 ϩ T cells, suggesting that a similar co-stimulatory function is provided so that T helper cells were not required.
In marked contrast to the results obtained with preactivated T cells (PHA blasts), the primary activation of resting T lymphocytes by CD80-transfected melanoma cells was inhibited in the presence of IL-12. This effect seems not to be restricted to SkMel63 melanoma cells since a similar suppression was observed when T lymphocytes were stimulated with CD80-transfected breast and ovarian cancer cells and exogenous IL-12 (31, B. Gü ckel, unpublished results). was mediated by IFN-γ. It was shown earlier that one of the physiological functions of macrophage-derived IL-12 is the induction of IFN-γ production from CD4 ϩ T cells (38, 42, 43) and many of the IL-12-mediated effects like induction of tumor Discussion regression in vivo were found to be accompanied by IFN-γ production (40,41,44). In addition to its stimulatory activity on Transfectants of the human melanoma cell line SkMel63 expressing CD80 and CD86 respectively were compared for macrophage function and expression of MHC molecules, IFN-γ is known to regulate the activation and differentiation of T their capacity to induce primary T cell activation. As a parameter we studied the proliferative response as well as lymphocytes. As a potent antiproliferative cytokine, IFN-γ inhibits proliferation of murine T h 2 T cell clones and is involved cytokine secretion of resting T lymphocytes towards alloantigens. We and others previously observed that unmodified in the induction of cell death (45, 46) .The sensitivity towards inhibitory effects of IFN-γ is regulated in T cells by the human tumor cell lines do not induce alloreactive T cells and that this response is dependent on co-stimulatory signals expression of the IFN-γ receptor β chain (47, 48) . The fact that IL-12 together with CD80-transfected melan-(30-32). Therefore, this experimental system seems suitable for the analysis of tumor cell modifications aimed at improving oma cells had different effects on resting versus preactivated T cells may be explained by our observation that preactivated their immunogenicity.
We found that both CD80 and CD86 transfectants induced T cells released less IFN-γ and, moreover, did not respond to exogenous IFN-γ when compared to resting T cells. The T cell activation to a similar extent, and that co-expression of CD80 and CD86 molecules did not further improve this reduced sensitivity for inhibitory effects of IFN-γ could be due to down-regulation of the IFN-γ receptor β chain or otherwise response. In our experiments T cell activation did not depend on the level of CD80/CD86 expression indicating that a related to the advanced activation status of these cells. It is striking that besides the similar functions of CD80 and critical albeit low level of these molecules as represented by SkMel63A3 cells is sufficient. The fact that co-expression of CD86 described above the stimulation of resting T cells with transfected melanoma cells in the presence of IL-12 or IFN-CD80 and CD86, as usually found on professional APC, did not enhance T cell activation may argue against a synergism γ points towards a different functional activity of CD80 and CD86. Indeed, different functions of CD80 and CD86 were between both molecules. CD80 and CD86 were reported before to be equally effective in the induction of anti-tumor suggested based on mAb inhibition in vivo (21) and stimulation of human T cells in combination with CD80-and CD86-responses in animal models (28,29). Experiments performed with transfected L-cells demonstrated that CD80 and CD86 transfected cells (20). These studies indicated that CD80 directs an immune response towards T h 1 T cells while CD86 provided similar co-stimulation for resting human T lymphocytes and that the stimulatory function of CD80 was not further supports T h 2 responses. Because we studied mixed T cell populations and not purified T helper cells, it is possible that enhanced by co-expressing CD86 (19) . These findings are in line with our data and interpretations.
IFN-γ and IL-4 which were produced here following stimulation with CD80 as well as with CD86 transfectants may originate Tumor cells providing optimal co-stimulation are expected to directly activate CD8 ϩ T lymphocytes without the help of from both CD4 ϩ and CD8 ϩ T cells. However, since CD80 and CD86 transfectants induced an identical cytokine profile, our CD4 ϩ T cells. This was indeed reported before for CD80-transfected human melanoma and acute monocytic leukemia findings argue against the notion that the opposite effects of CD80 and CD86 on resting T cells in the presence of IL-12 cell lines in vitro as well as for the induction of a tumorspecific response in vivo (32, 42) . Our experiments performed are related to activation of different T cell populations. CTLA-4 was shown to function as a negative regulator of T with purified CD8 ϩ T lymphocytes also suggest that the MHC class I and class II positive SkMel63 melanoma cells cell activation (23-25). Whether CTLA-4 ligation is involved in mediating the inhibitory effect of IL-12/IFN-γ is, however, stimulated CD8 ϩ T cells without CD4 ϩ T cell help following transfection with CD80. Moreover, CD86-transfected SkMel63 not known at present. The divergent effects of CD80 and
